Report

Regulation of the Proinflammatory Effects of Fas Ligand (CD95L)

Science  27 Nov 1998:
Vol. 282, Issue 5394, pp. 1714-1717
DOI: 10.1126/science.282.5394.1714

You are currently viewing the abstract.

View Full Text
As a service to the community, AAAS/Science has made this article free with registration.

Abstract

Fas ligand (CD95L) inhibits T cell function in immune-privileged organs such as the eye and testis, yet in most tissues CD95L expression induces potent inflammatory responses. With a stably transfected colon carcinoma cell line, CT26-CD95L, the molecular basis for these divergent responses was defined. When injected subcutaneously, rejection of CT26-CD95L was caused by neutrophils activated by CD95L. CT26-CD95L survived in the intraocular space because of the presence of transforming growth factor–β (TGF-β), which inhibited neutrophil activation. Providing TGF-β to subcutaneous sites protected against tumor rejection. Thus, these cytokines together generate a microenvironment that promotes immunologic tolerance, which may aid in the amelioration of allograft rejection.

  • * To whom correspondence should be addressed. E-mail: gnabel{at}umich.edu

View Full Text

Cited By...